ELEVATE Trial: Elacestrant Combos Boost PFS in ER+/HER2- Breast Cancer ...
4 days ago · Key Takeaways Elacestrant combined with everolimus or abemaciclib showed significant PFS benefits in ER-positive, HER2-negative metastatic breast cancer patients. The ELEVATE trial …
SABCS 2025 News: Updated EMBER-3 Efficacy Results for Imlunestrant …
3 days ago · Updated survival outcomes from the EMBER-3 trial reinforced the clinical benefit of imlunestrant as monotherapy and in combination with abemaciclib as oral, chemotherapy-free …
The Latest on Emerging Therapies for Metastatic HR+/HER2- Breast Cancer ...
4 days ago · Trials such as SERENA-6 are testing circulating tumor DNA (ctDNA) to guide treatment changes ahead of disease progression in patients with advanced breast cancer.
Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative ...
May 13, 2025 · In the phase II NIMBUS trial, patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) and high tumor mutational burden (TMB ≥ 9 …
Updates to the Management of HR-Positive, HER2-Negative Breast Cancer ...
May 31, 2024 · Metastatic hormone receptor–positive, HER2-negative breast cancer treatment is increasingly individualized as more of the tumor landscape is described and targeted therapies are …
Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy ...
4 days ago · as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior …
Neratinib Plus Capecitabine for the Treatment of Her2-Negative ...
This phase II trial tests how well neratinib in combination with capecitabine works in treating patients with HER2-negative breast cancer that has spread from where it first started (primary site) to other …
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative ...
Abstract Background: HER2 mutations are targetable alterations in patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC). In the SUMMIT basket study, patients with HER2 …
1 in 4 metastatic breast cancer patients treated with - GlobeNewswire
6 days ago · The post-hoc exploratory analysis of the MONALEESA-2, -3 and -7 trials in first-line HR+/HER2- MBC aimed to identify clinical characteristics and biomarkers of patients who …
Menarini Group Presents Elacestrant (ORSERDU) Phase 2 Combination …
6 days ago · The phase 2 portion evaluates this treatment regimen in patients with brain metastases. ELCIN (NCT05596409) is a phase 2 trial evaluating the efficacy of elacestrant in patients with ER+, …